TNFRSF8 and lymphoma: This was performed in the context of Brentuximab Vedotin (BV) treatment for lymphoma, a CD30 monoclonal antibody (Ab)-drug conjugate, where the response is not always correlated to CD30 expression detected by immunohistochemistry (IHC).